ASAmal Shervington

Amal Shervington

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amal Shervington has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Leroy Shervington

    University of Central Lancashire

    4 shared publications
  • Rahima Patel

    Brain Tumour North West, Faculty of Science and Technology, University of Central Lancashire, Preston, UK

    4 shared publications
  • Chen Lu

    Brain Tumour North West, Faculty of Science and Technology, University of Central Lancashire, Preston, UK

    3 shared publications
  • Dipti Thakkar

    Brain Tumour North West, Faculty of Science, University of Central Lancashire, Preston, UK

    2 shared publications
  • Gareth Roberts

    Faculty of Science and Technology, University of Central Lancashire, Preston, UK

    2 shared publications
  • Nichola Cruickshanks

    Neurosurgery Department, Royal Preston Hospital, Brain Tumor North West, Preston, UK

    2 shared publications

Latest Publications

  • Is CD133 the Appropriate Stem Cell Marker for Glioma?

    by Zarine Khan, Leroy Shervington, Amal Shervington

  • Telomerase downregulation in cancer brain stem cell

    by Amal Shervington, Chen Lu, Rahima Patel, Leroy Shervington

    Cancer stem cells (CSCs) are a minute sub-population of self-renewing, immortal cells, which can be responsible for chemoresistance observed in the treatment of cancer. CSCs are similar to cancer cells requiring telomerase activity or alternative mechanisms for their proliferation and regeneration. This study explored the correlation between CD133 (stem cell marker) and telomerase expression using CD133+ cells isolated from the glioma GOS-3 cell line with magnetic affinity cell sorting (MACS). GOS-3 CD133+ showed a transcription downregulation of hTERT (≈100-fold decrease) compared with CD133− cells. In order to further substantiate the novel finding, serum deprivation was adopted to enrich CD133 expression in GOS-3 cells. A pronounced upregulation of cd133 and downregulation of telomerase expression were produced as a consequence of decreasing serum supplement levels in GOS-3 cells. These findings showed for the first time that telomerase is downregulated in brain cancer stem cells compared to cancer cells.


  • Silencing DNA Methyltransferase (DNMT) Enhances Glioma Chemosensitivity

    by Amal Shervington, Rahima Patel

    Previously, we demonstrated that demethylation with 5-Aza-2′-deoxycytidine (5azadC) resulted in reduced levels of telomerase that led to telomere shortening, enhanced MGMT expression and enhanced chemosensitivity. Although the results were encouraging, the fact that 5azadC is highly toxic and nonspecific, thus is not favored as a therapeutic molecule. The aim of this research is to downregulate the DNA methyltransferase (DNMT1) gene using three sets of double-stranded RNA oligos designed to align different regions of DNMT1 sequence. Results showed the small-interfering RNA (siRNA) 1 and 3 demonstrated significant levels of silencing DNMT1 and hTERT transcription after 24-hour treatment (p = 0.01) and ~90% and 70% transcriptional downregulation of DNMT1 and hTERT, respectively after 48 hours. However, siRNA 2 downregulated DNMT1, hTERT, and MGMT in GOS-3 and U87-MG cells that was attributed to sequence homology between oligo 2 and MGMT complementary DNA. The siRNA-treated glioma cell lines GOS-3 and U87-MG were subjected to two chemotherapeutic agents; taxol and Temozolomide (TMZ). Results suggest that either a combination of siRNA 1 or 3 followed by taxol (2–6 μM) after 48 hours or a combination of siRNA 1 or 3 followed by TMZ (600–1000 μM) after 24 hours would be novel and effective glioma therapies.


  • The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin

    by Amal Shervington, Vidya Pawar, Sharad Menon, Dipti Thakkar, Rahima Patel

    Telomerase expression strongly correlates with the grade of malignancy in glioma with inhibition illustrating a definite increase in chemosensitivity. This study was designed to investigate the effects of a green tea derivative, epigallocatechin-3-gallate (EGCG); together with either cisplatin or tamoxifen in glioma, and to investigate whether these effects are mediated through telomerase suppression. EGCG showed a significant cytotoxic effect on 1321N1 cells after 24 h and on U87-MG cells after 72 h (P < 0.001) without significantly affecting the normal astrocytes. Treatment with EGCG inhibited telomerase expression significantly (P < 0.01) and enhanced the effect of cisplatin and tamoxifen in both 1321N1 (P < 0.01) and U87-MG (P < 0.001) cells. EGCG, as a natural product has enormous potential to be an anti-cancer agent capable of enhancing tumour cell sensitivity to therapy.


  • Differential hTERT mRNA processing between young and older glioma patients

    by A. Shervington, R. Patel

    The amplification of hTERT was detected in glioma tissues, although telomerase activity was not always found within these specimens. The aim of this study was to correlate the level of hTERT transcription with telomerase activity in two glioma age groups. hTERT was significantly transcribed at similar copy numbers in both age groups. However, these mRNAs translated to telomerase in 100% of the young compared to only 25% of the older patients. While hTERT transcription correlated directly to telomerase protein level and activity, as well as longer telomeres in the young group, such correlations were missing in the older group.


  • GPR26: A marker for primary glioblastoma?

    by Alan N. Carter, Clare L. Cole, Adam G. Playle, Emma J. Ramsay, Amal A. Shervington


  • Chemoresistance in gliomas

    by Chen Lu, Amal Shervington

    Despite improved knowledge and advanced treatments of gliomas, the overall survival rate for glioma patients remains low. Gliomas comprise of significant cell heterogeneity that contains a large number of multidrug resistant (MDR) phenotypes and cancer stem cells (CSCs), a combination that may contribute to the resistance to treatment. This article reviews the MDR related genes, major-vault protein (MVP), anti-apoptotic protein (Bcl-2) and the molecular mechanisms that may contribute to chemoresistance, in addition to the upregulated MDR phenotypes present in CSCs that has recently been identified in gliomas. Moreover, future potential therapies that modulate MDR phenotypes and CSCs are also reviewed. An improved understanding of MDR may lead to a combined treatment, targeting both CSCs and their protective MDR phenotypes leading eventually to attractive strategies for the treatment of gliomas.


  • Proteomics: The Tool To Bridge the Gap between the Facts and Fables of Telomerase

    by Dipti Thakkar, Amal Shervington

    Genomic analysis has provided a huge cohort of data that has shed light on the regulation and structure of telomerase and will continue to influence its study profoundly. However, genomic and proteomic data need to be collated in order to bridge the gap between telomerase regulation and its crucial role in carcinogenesis. This review highlights significant advances in understanding the regulation of telomerase activity in the realm of genomics and proteomics focusing on the importance of telomerase as a future prognostic and diagnostic marker.


  • Can The Lack of HSP90α Protein in Brain Normal Tissue and Cell Lines, Rationalise it as a Possible Therapeutic Target for Gliomas?

    by Amal Shervington, Nichola Cruickshanks, Robert Lea, Gareth Roberts, Tim Dawson, Leroy Shervington

    Despite studies suggesting a role for HSP90α in tumorigenesis, there are no reports as to its expression in normal human brain tissue. In this study, the expression of HSP90α was evaluated in both cell lines (3 gliomas and 2 controls) and brain tissue specimens of 10 patients (8 gliomas and 2 normal brain tissues). No HSP90α protein was detected in either normal cell lines or normal brain tissue. However, 8/8 glioma tissues and 3/3 glioma cell lines did express HSP90α. These findings provide a rationale for targeting HSP90α protein as a therapeutic candidate for glioma.


  • Expression of Multidrug Resistance Genes in Normal and Cancer Stem Cells

    by A. Shervington, C. Lu

    CD133 (stem marker) and drug resistant gene (mdr1 and bcl-2) expression were detected in human glioblastoma and normal brain tissues. Glioma tissues contained higher ratio of CD133+ cells compared to normal tissues (≈ 10 fold increase). The chemosensitivity assay showed that GOS-3 and NHA CD133+ possess greater resistance towards drugs compared to CD133- fractions. This study revealed for the first time that: a) serum deprivation enriched CD133 expression and demonstrated a direct co-expression between CD133 and drug resistant in GOS-3 cells and b) higher expression of CD133 and drug resistance were found in glioblastoma tissues in comparison to normal brain tissues.